Biocytogen-B (02315) Surges Over 8% in Early Trading Ahead of Q3 Results; Institutions Bullish on Further Earnings Growth

Stock News10-28

Biocytogen-B (02315) jumped more than 8% in early trading. As of press time, the stock was up 6.94% at HK$42.82, with a turnover of HK$31.214 million.

On the news front, Biocytogen plans to hold a board meeting on October 29 to approve its third-quarter results.

Biocytogen's interim results showed that in the first half of the year, the company achieved operating revenue of RMB 941 million, up 51.60% year-on-year; net profit attributable to shareholders was RMB 241 million, up 402.29% year-on-year. Driven by both overseas and domestic businesses, overseas revenue accounted for nearly 60% of main business revenue.

China Securities Co., Ltd. noted that Biocytogen's front-end business foundation is solid, and its back-end antibody partnerships are gradually entering a milestone realization phase. With the release of new capacity, continued dilution of expense ratios, and the advancement of licensing projects toward clinical stages, the company's profitability and earnings elasticity are expected to further improve.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment